Axsome Therapeutics Inc (AXSM) vs peers
$145.04
Latest weekly close · Market cap $7.5B
AXSM's EV/EBITDA is not meaningful or is unavailable. Choose another measure to compare peers.
Peer group: Pharmaceuticals. Updated .
| Stock | EV/EBITDA | Own 5-year percentile |
|---|---|---|
| AXSMAxsome Therapeutics Inc | n/a | n/a, not ranked |
| MRKMerck & Co. | 37.2× | 87 |
| PFEPfizer | 16.8× | 80 |
| VTRSViatris | 12.3× | 84 |
| ZTSZoetis | 10.3× | 9 |
| BMYBristol Myers Squibb | 9.4× | 42 |
| LLYLilly (Eli) | n/a | n/a, not ranked |
| Peer median | 12.3× |
How to read this comparison
Up to eight covered companies in the same industry, largest market value first.
EV/EBITDA divides enterprise value (market value plus debt, minus cash) by EBITDA over the last twelve months. The peer median leaves out AXSM and stocks without a reading.
Each percentile compares a stock with its own weekly readings over the last five years, so 20 means its EV/EBITDA is above 20% of its own past readings. It needs at least 26 weeks of history. It is not a rank against the other stocks in this table.
Different growth rates, margins and financial risks can explain different multiples. Stocks without positive EBITDA have no reading.
AXSM versus the peer median
n/a
- AXSM
- n/a
- Peer median
- 12.3×
- Own 5-year median
- n/a